Early psychedelic trials found no lasting benefits — and the methods were better than we thought

Key Findings

🧪 Stripping the Trip Out of Psychedelics Is a Category Error

• A commentary argues that engineering psychedelics to remove subjective experience — so-called "psychoplastogens" built for scalability — eliminates what the authors call the primary mechanism of action: the altered state itself.
• The piece draws on the concept of "ecodelics" to argue that set, setting, and social context aren't packaging around the drug — they're load-bearing. Pharmaceuticalizing psychedelics to fit existing medical infrastructure may optimize for the wrong outcome entirely.

💊 MDMA-Assisted Therapy Shows Broad PTSD Benefits Across 7 Trials

• A systematic review and meta-analysis covering seven randomized controlled trials found that MDMA-assisted therapy was associated with significant improvements in PTSD symptoms, dissociation, depression, and functional disability compared to controls — but not sleep quality.
• Key caveats: small sample sizes in some studies, blinding challenges inherent to psychedelic research, and the fact that a single sponsor funded all included trials. The signal is real; the independence of that signal is a fair question.

🔬 LSD Deconstructed: Researchers Found the Minimal Psychedelic Pharmacophore

• Scientists systematically dismantled LSD's four-ring chemical core into nine simplified analogues and tested each for receptor activity and hallucinogenic behavior in mice. They identified the minimum molecular structure needed to produce full hallucinogenic effects at the serotonin 2A receptor.
• Two analogues — UCD0094 and UCD0076 — showed improved safety profiles. UCD0076 notably preferred the serotonin 2C receptor over 2A and produced antipsychotic-like effects in behavioral assays, suggesting a possible path toward non-hallucinogenic therapeutic derivatives.

🐀 MDMA Reduced Alcohol Intake in High-Drinking Rats — Via the Amygdala

• In genetically selected alcohol-preferring rats, five days of MDMA administration reduced ethanol consumption without affecting anxiety-like behavior. Injections directly into the central amygdala replicated the effect 24 hours later; injections into the ventral tegmental area did not.
• The mechanism appears tied to changes in dynorphin and nociceptin gene expression in the amygdala and ventral tegmental area — two peptide systems already dysregulated in these rats. The effect was region-specific and didn't extend to the nucleus accumbens.

🍄 Psilocybin Restored Memory in Alzheimer's Rats — But Not the Underlying Brain Sync

• In a rat model of Alzheimer's-like pathology, psilocybin restored spatial memory performance. The catch: it did not restore the fronto-hippocampal synchrony — the coordinated brain activity between the prefrontal cortex and hippocampus — that is typically disrupted in this model and linked to cognitive decline.
• That dissociation matters. Memory improved, but the neural mechanism researchers expected to explain it didn't budge, which means the path from psilocybin to cognitive recovery is more complicated than it looked.

⚠️ Ayahuasca Plus Cough Medicine Sent a Man to the ICU

• A 46-year-old man developed severe serotonin syndrome with acute respiratory failure after combining three days of ayahuasca — which contains monoamine oxidase inhibitors — with over-the-counter dextromethorphan and diphenhydramine. He required emergency intubation and intensive care.
• He was extubated on day two and discharged on day three after treatment with benzodiazepines and cyproheptadine. The case is described as the first documented instance of this specific combination producing respiratory failure — a reminder that "natural" and "over-the-counter" is not the same as "safe to combine."